Equal improvements were found in the ability of the peripherally restricted CB1R blockade to reverse hepatocellular damage and hepatic steatosis, as manifested by reduced serum levels of ALT (Figure 6A,B), AST (Figure 6C,D), and hepatic TG content (Figure 6E,F), as well as a reduction in the elevated serum cholesterol levels (Figure 6G,H). Here, CNR1 is linked to Hepatic steatosis.